As the largest pharmaceutical company in Japan and one of the global leader of the industry, Takeda is commited to strive toward better health for people worlwide through leading innovation in medicine. More than 30,000 employees work toward discovering, developing, and delivering medicine that will improve patient's lives.
Takeda's mature market are japan, United Stated and Europe. The emerging market continue to grow such as Brazil, Rusia, and China.
In 1977, Takeda first entered the US pharmaceutical market by developing a joint venture with Abbot Laboratories caled TAP Pharmaceuticals. Through TAP Pharmaceutical, takeda and Abbot launched the blockbusters Lupron in 1985 and Prevacid in 1995.
Early this year, as reported on Takeda, the Japan's biggest pharmaceutical company and Enterome Bioscience SA announced they have entered into a strategic drug discovery collaboration to research potential new therapeutic directed at microbiome target. Enterome is pioneering the development of novel drugs and diagnostic to support personalized therapies in microbiome-related disease such as Gastrointestinal disorder disorders, cancer and metabolic diseses.
Enterome will receive an upront payment and 3-year R&D funding, and is eligible to receive additional payment for each molecule discovered through the collaboration in the form of open exercise, development, reguatory and commercial milestone payment. In addition, Enterome, Enterome is eligible to receive potential tiered royalites on the net sales of any product that commercialized by Takeda.
Also this year, Fierce Pharma Asia Noted that Takeda together with anGene, Inc. announced a strategic alliance to discover, develop and commercialized novel therapies for specialty gastrointestinal disease. Takeda makes use of enGene's experties and intellectual property position in delivering therapeutic genes to cells of the gut lining by using its proprietary non-viral vector platform.
"We are very excited to be collaborating with the team at Takeda to investigate new medicines for the specialty GI market using enGene's innovative gene delivery platform for the gut. This alliance provides our company an excellent opportunity to grow our drug development capabilities through working with a leading pharmaceutical company in the gastroenterology space," said Anthony T. Cheung, chief executive officer and co-founder of enGene as quoted from Business Wire.
Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda through pre-clinical proof of concept and IND enabling studies. At that point, Takeda will have an option to exclusively license the global rights for the product candidates. The both companies will also collaborate with enGene in developing Gene Pill ino a platform for ora delivery of antibodies. Takeda has also the exlusive option to obtain a right of first negotiation for up three antibody targets.
Join the Conversation